Dünyanın En Hızlı ve Pratik Kardiyak Test Cihazı: heArt²

Frend Cardiac Test cihazları LOC (Lab-on-a-chip) teknolojisi ile dizayn edilmiş teşhis üniteleri olup tek kullanımlık kit-disposable chip kullanmaktadır. Bu kitler üzerine bırakılan hasta örnekleri özel bir tanı ile tahlil edilerek teşhis konulur.

FREND™ taşınabilir yapısı, fluorometri okumasını yapar ve teşhisi yorumlayarak elektronik formatta bir rapor ile durumu belgeler.

FREND™  özel yönetim yazılımı ile tüm teşhis bilgileri bir tek merkezden doğrular ve destekler. Frend gerçek anlamda her yerde kullanıma uygun yapıda bir test cihazıdır.

Cardiac Markers

Kalp kasları zedelendiğinde hücre duvarları zayıflar ve normalde hücreler arasında  bulunan bazı protein ve enzimler kan dolaşım sistemine karışmasına izin verirler.  Kardiak belirleyiciler adı verilen bu maddeler kan örneklerinde özel bağışıklık testleriyle belirlenir ve teşhis edilirler. En sık görülen kardiak belirleyiciler ise  göğüs ağrısı ve akut miokardial Enfarktüs tanısına sebep olan CK-MB, Myoglobin ve Troponin-I dır.

CK-MB çoğunlukla hastanelerde miokardiyal hasarları tespitte kullanılır. Bu yakınlık ve kardiospesifik özellik; klinisyenler kardiyologlar için hasarları algılamadaki ilk değerdir ve hemen hemen herkes tarafından son derece iyi bilinir. Bununla beraber CK-MB tek başına kullanıldığında ideal bir tanımlayıcı değildir. Çünkü CK-MB düzeyleri hızlı bir tanı için yeterli olmayabilir ve belkide o seviyede bazı diğer koşulları elemine ediyor olabiliriz. CK-MB seviyesi tipik olarak exceed the upper limit of normal within three to eight hours of the onset of acute myocardial infarction, peaking within 10 to 24 hours, and returning to normal within two to three days. Additionally, CK-MB elevations occur as a result of chronic muscle disease and exercise.

Myoglobin is a protein that transports oxygen in muscle tissue, including the myocardium and skeletal muscle. Myoglobin is also present in smooth muscle. Following injury to any of these muscles, it appears in the blood more rapidly than any other marker. As early as one hour following the onset of chest pain, when CK-MB levels are still in the range of normal, myoglobin levels may already be elevated. This rapid appearance is due to myoglobin's location in the cell and its low molecular weight. Myoglobin exhibits high clinical sensitivity for acute myocardial infarction but poor specificity. Every patient with acute myocardial infarction will have elevated myoglobin in the early hours following the onset of chest pain; however, myoglobin elevations may also be indicative of skeletal muscle injury. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, recommend the use of myoglobin, a highly sensitive marker, within the first four to eight hours after onset in ruling out myocardial necrosis.

The troponin complex, found on the thin filament of the muscle contractile apparatus, consists of three protein sub-units: troponin I, troponin T and troponin C. Cardiac specific troponin I is used as an aid in the diagnosis of myocardial infarction since it becomes elevated in the blood approximately four to eight hours following myocardial injury or necrosis and remains elevated for several days. In addition to its utility in diagnosis, elevated troponin I levels convey prognostic information and have been shown to identify patients having an increased risk of death. According to the ACC/AHA guidelines, a cardiac-specific troponin (such as troponin I) is the preferred marker for diagnosing cardiac injury.4 However, troponin I does have some disadvantages as well, including low sensitivity in the early phase of myocardial infarction (< six hours after symptoms onset) and its limited ability to detect late minor reinfarction.

For RAPID (just 5 min.) and QUANTITATIVE immunoassay using small sample volume (less than 20 ? of hole blood, PERIPHERAL BLOOD available), brand-new platform (FRENDTM panel, patent pending) is developed. A traditional membrane is totally excluded as a sample flow and a reaction media. Therefore, sample, reaction and adsorption pads have been replaced by several micro-fluidic components which have been optimized for a FRENDTM panel. It is also produced cost-effectively with a simple injection molding process. The stability and reliability of a multi-step immunoassay is a critical point, especially in a quantitative immunoassay. Our Bio R&D Processing Part developed an optimized sample preparation protocols and process control reagents for Bio-Processing in a FRENDTM panel. These reagents are treated at the surface of FRENDTM panel, which is ready to use cartridge. Therefore, user can use FRENDTM panel by just simple blood sample injection.

FREND 2010 Programı